Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xencor Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xencor Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xencor Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Xencor Raises US$7.6 Million In Venture Financing 11
Partnerships 12
Applied BioMath Enters into Partnership with Xencor 12
Selexis Enters into Agreement with Xencor 13
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 14
Licensing Agreements 15
Xencor Enters into Licensing Agreement with Selexis 15
INmune Bio Enters into Licensing Agreement with Xencor 16
Novartis Enters into Licensing Agreement with Xencor 17
Xencor Enters into Licensing Agreement with Selexis for XmAb-13676 18
Xencor Enters into Licensing Agreement with Receptor Logic 19
Xencor Enters Licensing Agreement with Catalent Pharma Solutions 20
Xencor Enters into Licensing Agreement with Selexis 21
Amgen Enters into Licensing Agreement with Xencor 22
Xencor Enters Into Licensing Agreement With Merck 24
CSL Enters into Licensing Agreement with Xencor 25
Xencor Enters into Licensing Agreement with Alexion Pharma 26
sAber Bioscience Enters Into Licensing Agreement With Xencor For XmAb Technology 28
FPRT Bio Enters into Licensing Agreement with Xencor for XPro1595 29
Equity Offering 30
Xencor Prices Public Offering of Shares for USD226.3 Million 30
Xencor Raises USD126.5 Million in Public Offering of Shares 32
Xencor Raises USD123 Million in Public Offering of Shares 34
Xencor Completes IPO For US$80.5 Million 36
Xencor Inc – Key Competitors 38
Xencor Inc – Key Employees 39
Xencor Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Jan 05, 2018: Xencor Announces 2018 Priorities and Expected Milestones 41
Financial Announcements 43
Aug 06, 2018: Xencor announces second quarter 2018 financial results 43
May 07, 2018: Xencor Announces First Quarter 2018 Financial Results 45
Feb 27, 2018: Xencor Reports Fourth Quarter and Full Year 2017 Financial Results 47
Nov 07, 2017: Xencor Reports Third Quarter 2017 Financial Results 50
Aug 07, 2017: Xencor Reports Second Quarter 2017 Financial Results 53
May 09, 2017: Xencor Reports First Quarter 2017 Financial Results 55
Feb 28, 2017: Xencor Reports Fourth Quarter and Full Year 2016 Financial Results 57
Corporate Communications 60
Dec 19, 2017: Xencor Appoints Richard Ranieri to Board of Directors 60
Mar 06, 2017: Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders 61
Clinical Trials 62
Mar 01, 2017: Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research 2017 Annual Meeting 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
Xencor Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xencor Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xencor Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Xencor Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xencor Raises US$7.6 Million In Venture Financing 11
Applied BioMath Enters into Partnership with Xencor 12
Selexis Enters into Agreement with Xencor 13
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 14
Xencor Enters into Licensing Agreement with Selexis 15
INmune Bio Enters into Licensing Agreement with Xencor 16
Novartis Enters into Licensing Agreement with Xencor 17
Xencor Enters into Licensing Agreement with Selexis for XmAb-13676 18
Xencor Enters into Licensing Agreement with Receptor Logic 19
Xencor Enters Licensing Agreement with Catalent Pharma Solutions 20
Xencor Enters into Licensing Agreement with Selexis 21
Amgen Enters into Licensing Agreement with Xencor 22
Xencor Enters Into Licensing Agreement With Merck 24
CSL Enters into Licensing Agreement with Xencor 25
Xencor Enters into Licensing Agreement with Alexion Pharma 26
sAber Bioscience Enters Into Licensing Agreement With Xencor For XmAb Technology 28
FPRT Bio Enters into Licensing Agreement with Xencor for XPro1595 29
Xencor Prices Public Offering of Shares for USD226.3 Million 30
Xencor Raises USD126.5 Million in Public Offering of Shares 32
Xencor Raises USD123 Million in Public Offering of Shares 34
Xencor Completes IPO For US$80.5 Million 36
Xencor Inc, Key Competitors 38
Xencor Inc, Key Employees 39
Xencor Inc, Other Locations 40
List of Figures
Xencor Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xencor Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9